Package 0093-5234-56

Brand: efavirenz, emtricitabine and tenofovir disoproxil fumarate

Generic: efavirenz, emtricitabine and tenofovir disoproxil fumarate
NDC Package

Package Facts

Identity

Package NDC 0093-5234-56
Digits Only 0093523456
Product NDC 0093-5234
Description

30 TABLET, FILM COATED in 1 BOTTLE (0093-5234-56)

Marketing

Marketing Status
Marketed Since 2020-10-01
Brand efavirenz, emtricitabine and tenofovir disoproxil fumarate
Generic efavirenz, emtricitabine and tenofovir disoproxil fumarate
Sample Package No

Linked Drug Pages (1)

Raw FDA Data

View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "c1a1b151-9dea-485b-a42b-3483fb4ef7d7", "openfda": {"nui": ["N0000175463", "N0000175460", "N0000009948", "N0000190118", "N0000187064", "N0000185504", "N0000182140", "N0000182141", "N0000175462", "M0015066", "N0000009947"], "unii": ["JE6H2O27P8", "G70B4ETF4S", "OTT9J7900I"], "rxcui": ["643066"], "spl_set_id": ["fc9c2149-8d40-401b-af13-5ae7f953950a"], "pharm_class_cs": ["Nucleosides [CS]"], "pharm_class_epc": ["Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET, FILM COATED in 1 BOTTLE (0093-5234-56)", "package_ndc": "0093-5234-56", "marketing_start_date": "20201001"}], "brand_name": "Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate", "product_id": "0093-5234_c1a1b151-9dea-485b-a42b-3483fb4ef7d7", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Non-Nucleoside Analog [EXT]", "Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleosides [CS]", "Nucleosides [CS]"], "product_ndc": "0093-5234", "generic_name": "Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate", "labeler_name": "Teva Pharmaceuticals USA, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate", "active_ingredients": [{"name": "EFAVIRENZ", "strength": "600 mg/1"}, {"name": "EMTRICITABINE", "strength": "200 mg/1"}, {"name": "TENOFOVIR DISOPROXIL FUMARATE", "strength": "300 mg/1"}], "application_number": "ANDA091215", "marketing_category": "ANDA", "marketing_start_date": "20201001", "listing_expiration_date": "20261231"}